Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans
In the authors' words
Inducing a broadly neutralizing antibody (bnAb) response is a key goal of HIV-1 vaccine development. Despite significant progress, it is unknown whether vaccine-primed B cells can be reactivated and matured to secrete bona fide bnAbs. In the IAVI C107/C110 single-arm, open-label human trial, VRC01-class memory B cells previously primed by the GT1.1 germline-targeting envelope glycoprotein (Env) trimer were reactivated by a BG505 SOSIP.664 trimer boost. Somatic hypermutation in the activated B cells drove higher antibody affinity for the CD4-binding site on fully glycosylated, heterologous Env trimers. Three VRC01-class monoclonal antibodies derived from independent B cell lineages neutralized 18-31% of 119 viruses in a globally diverse panel. This work advances the HIV-1 germline-targeting vaccination concept from proof-of-priming towards proof-of-breadth and defines a benchmark for bnAb induction.
In plain words AI summary
In a human trial, they gave a second vaccine shot to people who had received an earlier HIV vaccine. This reactivated memory immune cells and improved the antibodies' ability to bind to a key site on HIV. Three antibodies from different cell lineages neutralized 18-31% of 119 diverse HIV viruses. The study moves HIV vaccine research from showing priming works toward showing it can produce broad protection.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source. 1 sentence was removed for not being supported by the abstract.
Appeared: Tuesday, October 27. bioRxiv. Preprint, not yet peer-reviewed.